Esophagogastric Cancer Clinical Trial
Official title:
A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia
Verified date | May 2024 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | February 23, 2025 |
Est. primary completion date | February 23, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 or older - Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at MSKCC - Has incurable disease defined as at least one of the following: - Presence of metastases to other organs (Stage IV), now or previously - Has locally advanced disease and are not candidates for surgery or more radiation treatment - Has received the maximal radiation therapy to the primary site, or has been assessed by radiation oncology as not being a candidate for chemoradiation therapy. - Karnofsky performance status >/= 50% - No endoluminal stent in place at the time of treatment - Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure - Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) </= 7 days prior to treatment - Prior radiation or surgery to the esophagus is permitted for patients with locally recurrent/persistent disease - Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2) - Adequate organ function defined at baseline as: - ANC =1,000/ L - Platelets =75,000/ L - Hb =8.5 g/dl - INR =1.5 (except for patients who are on full-dose warfarin) - Calculated creatinine clearance =50 ml/min (using Cockcroft-Gault method) - Total serum bilirubin =1.5 mg/dL, or </= 2.5 mg/dL for patients with a known history of Gilbert's syndrome - AST/ALT =5× upper limit of normal - Able to provide written informed consent Exclusion Criteria: - Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include: - Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic =12 consecutive months) - Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml - Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence of where the partner is sterile - T4 tumors with involvement of any adjacent structure, including the trachea, aorta or pleura - Prior history of esophageal perforation - Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study |
Country | Name | City | State |
---|---|---|---|
Israel | Weizmann Institute of Science | Re?ovot | |
United States | Memorial Sloan - Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Steba Biotech S.A., Weizmann Institute of Science |
United States, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated laser fluence rate | The maximally tolerated laser light fluence rate (mW/cm) of light exposure for VTP of malignant obstruction due to esophagogastric cancer will be measured by examining 6 fluence rates beginning with a fluence rate of 150 nW/cm, then increasing by 50mW/cm, up to a maximum of 400 mW/cm (150, 200, 250 300, 350, 400). | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05612048 -
A Study of Tooth Erosion in People With Esophagogastric Cancer
|
N/A | |
Completed |
NCT04161781 -
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
||
Completed |
NCT01803282 -
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05796102 -
PET-MRI Esophagus Feasibility Study
|
N/A | |
Recruiting |
NCT04656041 -
Folfox+Irinotecan+Chemort In Esophageal Cancer
|
Phase 2 | |
Withdrawn |
NCT02296671 -
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
|
Phase 2 | |
Active, not recruiting |
NCT04757363 -
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
|
Phase 2 | |
Completed |
NCT02023996 -
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
|
N/A | |
Recruiting |
NCT05117931 -
A Study of Amivantamab in People With Esophagogastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
Completed |
NCT01167114 -
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
|
Phase 2 |